T Cell News and Research

Latest T Cell News and Research

STSI joins JAX consortium to develop targeted cancer therapies

The Scripps Translational Science Institute (STSI) of San Diego, Calif., has joined a national consortium of research institutions headed by The Jackson Laboratory (JAX) that is building a library of primary human tumors with the goal of developing highly targeted cancer therapies.

30 Jun 2011

Researchers develop way to uncover evolution of human cancer cells

A team of researchers led by scientists at the University of California, San Francisco has developed a way to uncover the evolution of human cancer cells, determining the order in which mutations emerge in them as they wend their way from a normal, healthy state into invasive, malignant masses.

30 Jun 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

RxMD and GlycoRegImmune enter drug development collaboration

RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.

29 Jun 2011

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

GenSpera, Inc. has entered into a cooperation agreement with the University of Copenhagen, in Copenhagen, Denmark, to collaborate on the "SPOTLight" (Sustainable Production of Thapsigargin using Light) project.

29 Jun 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011

FamilyCord launches advanced cord tissue stem cell processing and storage

FamilyCord, one of the nation's leading cord blood banks, today announced their latest contribution to the advancement of the umbilical cord blood and tissue storage industry: CordTissuePlus.

29 Jun 2011

DMI completes rHEALTH sensor reduced-gravity experiments for NASA FAST program

In September 2010, the DNA Medicine Institute (DMI) successfully completed reduced-gravity experiments on its rHEALTH sensor for the NASA Facilitated Access to the Space Environment for Technology (FAST) program. NASA recently followed that experiment with a $190,000 contract to DMI to analyze data from the parabolic flights.

29 Jun 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

Convergen LifeSciences, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.

29 Jun 2011

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.

29 Jun 2011

Some adult survivors of childhood cancer are at risk for multiple cancers

The largest study yet of adult childhood cancer survivors found that the first cancer is just the beginning of a lifelong battle against different forms of the disease for about 10 percent of these survivors.

29 Jun 2011

Diet sodas and artificial sweeteners may not be healthy alternatives

In the constant battle to lose inches or at least stay the same, we reach for the diet soda. Two studies presented June 25 and 27 at the American Diabetes Association's Scientific Sessions in San Diego suggest this might be self-defeating behavior.

29 Jun 2011

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.

29 Jun 2011

Rodent olfaction and the chemistry of instinct

The mechanics of instinctive behavior are mysterious. Even something as simple as the question of how a mouse can use its powerful sense of smell to detect and evade predators, including species it has never met before, has been almost totally unknown at the molecular level until now.

29 Jun 2011

Nuvilex to continue development of acquired live-cell encapsulation technology

Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.

29 Jun 2011

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases. Five of the most exciting developments in this rapidly advancing field are presented in a series of articles in the June issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc..

29 Jun 2011

Start of clinical validation study of Down’s syndrome diagnostic test

In conjunction with several Central European prenatal centers, scientists at GATC Biotech AG and LifeCodexx AG have begun the clinical validation study of a non-invasive, prenatal diagnostic test based on next generation sequencing.

28 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).

28 Jun 2011

T Cell News and Research

Latest T Cell News and Research

STSI joins JAX consortium to develop targeted cancer therapies

Researchers develop way to uncover evolution of human cancer cells

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

RxMD and GlycoRegImmune enter drug development collaboration

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

FamilyCord launches advanced cord tissue stem cell processing and storage

DMI completes rHEALTH sensor reduced-gravity experiments for NASA FAST program

Amorfix fiscal 2011 net loss decreases to $3,330,437

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

Some adult survivors of childhood cancer are at risk for multiple cancers

Diet sodas and artificial sweeteners may not be healthy alternatives

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

Rodent olfaction and the chemistry of instinct

Nuvilex to continue development of acquired live-cell encapsulation technology

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Start of clinical validation study of Down’s syndrome diagnostic test

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in